Medi-Physics full-scale launch of cardiac imaging agent Myoview planned for April.
This article was originally published in The Gray Sheet
Executive Summary
MEDI-PHYSICS' MYOVIEW SCINTIGRAPHIC CARDIAC IMAGING AGENT Full-scall launch is slated for April, the company says. Approved by FDA Feb. 9, Myoview (technetium Tc99m tetrofosmin) is indicated for "scintigraphic imaging of the myocardium following separate administrations under exercise and resting conditions." The product is "useful in the delineation of regions of reversible myocardial ischemia in the presence or absence of infarcted myocardium," labeling states.
You may also be interested in...
Nycomed Amersham's Myoview Approvable For Rx Stress Testing Indication
Nycomed Amersham Imaging says it has received word from FDA that its Myoview kit for the preparation of technetium Tc-99m tetrofosmin is approvable for use with pharmacologic stress agents.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.